Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03497624 · ClinicalTrials.gov registry record
ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Completed
- Registry status
- 5
- Enrollment target
NCT03497624 is a clinical trial that has completed, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 5 participants.
The verdict
NCT03497624 has completed, sponsored by Addario Lung Cancer Medical Institute.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient derived PDX models will have no immediate benefit to the patient from whom the tumor specimen was obtained. Rather, these PDX models will be used to inform the study of ROS1-fusion driven cancers at large.
Interventions
- OTHER Biospecimens collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2020-09-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03497624
The ClinicalTrials.gov registry entry for NCT03497624 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addario Lung Cancer Medical Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biospecimens collection is the first listed.
NCT03497624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03497624 about?
NCT03497624 is a clinical study titled "ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors". Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient der...
What is the current status of trial NCT03497624?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-04-23. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03497624?
The interventions under investigation include: Biospecimens collection (OTHER).
Who is sponsoring clinical trial NCT03497624?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.